Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite ...

Ocean Biomedical , Inc. (NASDAQ:OCEA), a pharmaceutical company based in Providence, Rhode Island, disclosed the sale of unregistered equity securities in a recent filing with the Securities and ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...